Efficacy and Safety of Rimonabant on Weight Loss and Frequency of Binge Episodes in Obese Patients
Status:
Completed
Trial end date:
2005-08-01
Target enrollment:
Participant gender:
Summary
The primary objective is to assess the effect of rimonabant compared to placebo on weight
loss over a period of 6 months when prescribed with a mild hypocaloric diet in obese patients
with binge eating disorder.
The secondary objectives are:
- to assess the effect of rimonabant on the number of binge episodes per week, to assess
the effect of rimonabant on eating behavior using the Binge Eating Scale (BES) and Three
Factor Eating Questionnaire (TFEQ),
- to evaluate the safety and tolerability of rimonabant over a period of 6 months.